Payment overview · 2025
General Payments
$569.00
34 reported records · 10 companies
Healthcare provider profile · identity verified
Moustafa M Eldick, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · CRESCENT CITY, FL · NPI 1962592907
Verified facts
What the public records show
CMS Open Payments records show Moustafa M Eldick, M.D. received $569.00 in general payments during 2025 across 34 reported records.
GlaxoSmithKline, LLC. accounted for 34.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $197.67 | 34.7% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $72.87 | 12.8% | 4 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $63.53 | 11.2% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.15 | 10.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $58.08 | 10.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.78 | 8.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.47 | 3.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.16 | 3.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.18 | 2.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.11 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $569.00 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $197.67 | 15 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $63.53 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $58.08 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $31.61 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.44 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.15 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.11 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 58 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 118 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 174 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
174 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
58 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
90 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
211 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
118 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1313 | 165 |
| Gabapentin | Gabapentin | 1104 | 209 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1043 | 234 |
| Amlodipine Besylate | Amlodipine Besylate | 896 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 765 | 168 |
| Furosemide | Furosemide | 624 | 149 |
| Omeprazole | Omeprazole | 622 | 151 |
| Lisinopril | Lisinopril | 567 | 154 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 564 | 67 |
| Trazodone Hcl | Trazodone Hcl | 465 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 463 | 109 |
| Tizanidine Hcl | Tizanidine Hcl | 455 | 108 |
| Pantoprazole Sodium | Pantoprazole Sodium | 449 | 110 |
| Tamsulosin Hcl | Tamsulosin Hcl | 445 | 115 |
| Losartan Potassium | Losartan Potassium | 439 | 112 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 419 | 112 |
| Clopidogrel | Clopidogrel Bisulfate | 395 | 91 |
| Clonazepam | Clonazepam | 389 | 63 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 386 | 110 |
| Prednisone | Prednisone | 379 | 160 |
| Metformin Hcl | Metformin Hcl | 378 | 89 |
| Alprazolam | Alprazolam | 375 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 362 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 355 | 45 |
| Simvastatin | Simvastatin | 329 | 80 |
| Tramadol Hcl | Tramadol Hcl | 328 | 77 |
| Azithromycin | Azithromycin | 315 | 194 |
| Potassium Chloride | Potassium Chloride | 312 | 77 |
| Eliquis | Apixaban | 308 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 296 | 86 |
| Sertraline Hcl | Sertraline Hcl | 287 | 65 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 268 | 53 |
| Buspirone Hcl | Buspirone Hcl | 264 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 261 | 70 |
| Carvedilol | Carvedilol | 258 | 66 |
| Amoxicillin | Amoxicillin | 250 | 129 |
| Diclofenac Sodium | Diclofenac Sodium | 228 | 51 |
| Famotidine | Famotidine | 222 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 220 | 40 |
| Montelukast Sodium | Montelukast Sodium | 212 | 63 |
| Trulicity | Dulaglutide | 211 | 38 |
| Levofloxacin | Levofloxacin | 208 | 120 |
| Fluticasone Propionate | Fluticasone Propionate | 207 | 64 |
| Naproxen | Naproxen | 205 | 51 |
| Meloxicam | Meloxicam | 203 | 46 |
| Quetiapine Fumarate | Quetiapine Fumarate | 192 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 181 | 41 |
| Citalopram Hbr | Citalopram Hydrobromide | 176 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 174 | 32 |
| Allopurinol | Allopurinol | 172 | 43 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 172 | 114 |
| Duloxetine Hcl | Duloxetine Hcl | 172 | 32 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 165 | 32 |
| Ondansetron Hcl | Ondansetron Hcl | 163 | 58 |
| Ibuprofen | Ibuprofen | 162 | 46 |
| Memantine Hcl | Memantine Hcl | 157 | 31 |
| Methocarbamol | Methocarbamol | 157 | 50 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 155 | 24 |
| Donepezil Hcl | Donepezil Hcl | 150 | 33 |
| Alendronate Sodium | Alendronate Sodium | 146 | 31 |
| Baclofen | Baclofen | 139 | 32 |
| Temazepam | Temazepam | 139 | 25 |
| Clonidine Hcl | Clonidine Hcl | 136 | 29 |
| Celecoxib | Celecoxib | 135 | 27 |
| Glimepiride | Glimepiride | 133 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 130 | 27 |
| Atenolol | Atenolol | 128 | 31 |
| Mirtazapine | Mirtazapine | 123 | 27 |
| Meclizine Hcl | Meclizine Hcl | 122 | 49 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 121 | 73 |
| Ezetimibe | Ezetimibe | 120 | 34 |
| Lactulose | Lactulose | 119 | 43 |
| Ozempic | Semaglutide | 118 | 27 |
| Diazepam | Diazepam | 116 | 17 |
| Megestrol Acetate | Megestrol Acetate | 115 | 26 |
| Finasteride | Finasteride | 112 | 23 |
| Pregabalin | Pregabalin | 110 | 26 |
| Spironolactone | Spironolactone | 109 | 28 |
| Azelastine Hcl | Azelastine Hcl | 108 | 35 |
| Cephalexin | Cephalexin | 108 | 71 |
| Promethazine Hcl | Promethazine Hcl | 108 | 23 |
| Methadone Hcl | Methadone Hcl | 106 | suppressed |
| Latanoprost | Latanoprost | 99 | 20 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 98 | 41 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 96 | 29 |
| Lorazepam | Lorazepam | 91 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 91 | 22 |
| Mounjaro | Tirzepatide | 90 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 89 | 21 |
| Topiramate | Topiramate | 88 | 16 |
| Olanzapine | Olanzapine | 87 | 19 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 85 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 85 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 85 | 25 |
| Bumetanide | Bumetanide | 81 | 21 |
| Metoclopramide Hcl | Metoclopramide Hcl | 79 | 17 |
| Levetiracetam | Levetiracetam | 78 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 78 | 19 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 22 |
| Ventolin Hfa | Albuterol Sulfate | 77 | 26 |
| Buprenorphine Hcl | Buprenorphine Hcl | 76 | suppressed |
| Nystatin | Nystatin | 76 | 37 |
| Divalproex Sodium | Divalproex Sodium | 75 | 18 |
| Fluconazole | Fluconazole | 75 | 36 |
| Vraylar | Cariprazine Hcl | 74 | 14 |
| Xarelto | Rivaroxaban | 72 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 71 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 70 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 19 |
| Propranolol Hcl | Propranolol Hcl | 69 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 68 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 67 | suppressed |
| Sucralfate | Sucralfate | 67 | 21 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 16 |
| Farxiga | Dapagliflozin Propanediol | 63 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 63 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 60 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 58 | 22 |
| Jardiance | Empagliflozin | 58 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 55 | 13 |
| Levemir Flexpen | Insulin Detemir | 55 | 12 |
| Glipizide | Glipizide | 54 | 17 |
| Risperidone | Risperidone | 54 | 13 |
| Aripiprazole | Aripiprazole | 53 | suppressed |
| Linzess | Linaclotide | 53 | 12 |
| Methotrexate | Methotrexate Sodium | 53 | suppressed |
| Nitroglycerin | Nitroglycerin | 53 | 22 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 51 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 46 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | suppressed |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 43 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Bupropion Xl | Bupropion Hcl | 41 | 14 |
| Methimazole | Methimazole | 41 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 41 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 12 |
| Metformin Hcl Er | Metformin Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 36 | suppressed |
| Constulose | Lactulose | 35 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 35 | 13 |
| Ondansetron Odt | Ondansetron | 35 | 15 |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 34 | 14 |
| Clozapine | Clozapine | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 33 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Humalog | Insulin Lispro | 33 | suppressed |
| Metronidazole | Metronidazole | 33 | 24 |
| Risperidone Er | Risperidone Microspheres | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Carbamazepine | Carbamazepine | 31 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 31 | suppressed |
| Tradjenta | Linagliptin | 31 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 21 |
| Digoxin | Digoxin | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 13 |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Acyclovir | Acyclovir | 28 | 14 |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 28 | suppressed |
| Ketoconazole | Ketoconazole | 28 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 26 | suppressed |
| Mupirocin | Mupirocin | 26 | 20 |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Folic Acid | Folic Acid | 25 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Ubrelvy | Ubrogepant | 25 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Indomethacin | Indomethacin | 24 | 11 |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Klor-Con 10 | Potassium Chloride | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 20 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 18 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 16 | 14 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Lofena | Diclofenac Potassium | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Dulera | Mometasone/Formoterol | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Restasis | Cyclosporine | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Combigan | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Propylthiouracil | Propylthiouracil | 12 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Budesonide Dr | Budesonide | 11 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 11 | suppressed |
| Cosentyx Sensoready Pen | Secukinumab | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $569.00 · 34 records | GlaxoSmithKline, LLC. | CAPLYTA, Cologuard Collection Kit, JARDIANCE, JOURNAVX, NEXLETOL, OTEZLA, Ozempic, QULIPTA, REPATHA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error